Chemotherapy increases toxicity of the body, harms the immune system and can have some very health damaging side effects.
Patients often suffer from severe side effects and functional defects due to radiotherapy. Tumours need to be identified and discrete as this is not a cell-based treatment.
Cutting the cancer tissue out can be a fast method to remove the tumour, but if cancer tissue remains undiscovered, the cancer may continue to develop.
Therapies that reinforce the body’s natural abilities to fight cancer are supported by scientists around the globe. If there is hope in the fight against cancer, it is certainly in Immunotherapy.
If the immune system is fully functional, it has the astonishing ability to kill cancer cells on its own. Even in a healthy body, every day up to 150,000 cancer cells can appear and be removed by the immune system. Dendritic cells – the ‘generals’- in the immune system are informed about the enemy cells and from there they activate T-cells and killer cells – the ‘soldiers’. Each soldier cell can kill exactly one enemy cell. DCT can produce about 40 to 60 billion of these cells per day.
Immucura conducted a comprehensive cancer statistics and survival rates study, from December 2020 to April 2023, focusing on breast cancer cases, to determine the efficacy of Dendritic Cell Therapy (DCT) on breast cancer. The data indicate that breast cancer represented a significant proportion of cases at Immucura, accounting for 22.2% of all cancer cases during the specified period. Most breast cancer patients had advanced and severe grade 4 cancers (69.2%), and approximately 73.1% of them presented with metastatic breast cancer.
Regarding survival rates for breast cancer patients when undergoing Dendritic Cell Therapy, the data showed promising outcomes. Over one year, all 23 breast cancer patients survived, resulting in a 100% survival rate. At 3 years, the survival rate remained high at 87.5%, followed by 78.6% at 5 years. However, the 10-year survival rate decreased to 25%, suggesting ongoing challenges with long-term survival for breast cancer patients.
Dendritic Cell Therapy is a groundbreaking immunotherapy approach that has shown promise in various cancer types, including breast cancer. DCT involves using a patient’s own cells (dendritic cells) to stimulate an immune response against cancer cells, making it a promising approach for breast cancer therapy.
Cancer is the highest cause for premature death, but in the last 15 years there were only two Nobel Medicine prizes granted in the battle against cancer. Both of them were for immunotherapy (in 2011 to R. Steinman, and in 2018 to P. Allison and T. Honjo) and if there is hope in cancer health, it is in Immunotherapy.
While Allison and Honjo opened up the cancer cells for the immune attack with a specific chemotherapy, Steinman empowered the immune system to uncover the cancer cells naturally. Dendritic cells can detect and expose malignant cells with so-called ‘killer cells’ (NK, T-cells or T-lymphocytes) before they multiply and cause further damage to the body. Therapies that enhance the capacity of the body to fight cancer are supported by scientists all over the world. This approach teaches the body’s immune system how to expose and kill cancer cells. As it is a natural effect, DCT has no side effects.
Since 2014, Immucura has been helping patients to fight cancer with the most advanced scientific breakthroughs in Cancer Health. Immunotherapies have proven to be a very effective, minimally non-invasive weapon against cancer. They are the key elements in Immucura’s integrative approach. Immucura is specialised in Dendritic Cell Therapy (DCT), as well as Macrophage Activation Therapy (MAT), Natural Killer Cell Therapy (NKT) and Nanothermia. We also offer blood analysis, nutritional advice, targeted supplementation and other complementary treatments.
Cell based Immunotherapy can be the last hope for many cancer patients. Its effectiveness depends on the strength of the patient’s immune system. And of course, we don’t simply assume that the cancer patient’s immune system is strong. We have found a way to make the immune system more receptive and smarter. Seriously ill patients can then also benefit from immunotherapy with dendritic cells.
Dr. Ramon Simon-Lopez
Past Medical Director, Immucura Limited
When the body is stressed less by the side effects of the cancer therapy, the effect of the adjuvant therapies can be more effective in fighting the cancer etiology (the origin or cause of the disease). DCT can be applied before or during another therapy, without excluding any other treatment options.
© 2023 Immucura. All Rights Reserved
